A multicenter, retrospective study to asses the safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma
Latest Information Update: 08 Dec 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Dec 2020 New trial record
- 01 Nov 2020 Results published in the International Journal of Hematology